Roche Gets FDA Approval for Cancer-Treatment Test

By Matt Grossman

Roche Holding AG has gained approval from the U.S. Food and Drug Administration for a diagnostic test used to determine whether patients with endometrial cancer will benefit from a particular treatment.

The test, called Ventana MMR RxDx, can help physicians decide whether an endometrial cancer patient should be treated with Jemperli, an anti-PD1 immunotherapy from GlaxoSmithKline PLC.

The test uses a comprehensive panel of DNA mismatch repair biomarkers tested by immunohistochemistry, Roche said.

Write to Matt Grossman at [e-mail]

(END) Dow Jones Newswires

04-23-21 0632ET